Christina Schilder and her co-authors from The Netherlands Cancer Institute in Amsterdam (Journal of Clinical Oncology, Volume 28, Pages 1294-1300, 2010), studied patients before hormonal therapy and after receiving either tamoxifen (80 patients),
exemestane (99 patients) or healthy control women (120 individuals). They tested patients before and after 1 year of treatment.
The results were very surprising.